Analysts: ViroPharma Inc (VPHM.OQ)
VPHM.OQ on NASDAQ Stock Exchange Global Select Market
32.00USD
1 Aug 2013
32.00USD
1 Aug 2013
Price Change (% chg)
$-2.32 (-6.76%)
$-2.32 (-6.76%)
Prev Close
$34.32
$34.32
Open
$32.70
$32.70
Day's High
$33.16
$33.16
Day's Low
$31.40
$31.40
Volume
895,421
895,421
Avg. Vol
232,585
232,585
52-wk High
$35.18
$35.18
52-wk Low
$19.59
$19.59
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Outperform | 0.06 | December | 1 Aug 2013 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 8 | 8 | 8 | 8 |
| (2) OUTPERFORM | 4 | 4 | 4 | 4 |
| (3) HOLD | 4 | 4 | 4 | 4 |
| (4) UNDERPERFORM | 0 | 0 | 0 | 0 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 1.75 | 1.75 | 1.75 | 1.75 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-13 | 14 | 114.38 | 116.81 | 110.87 | 107.94 |
| Quarter Ending Dec-13 | 14 | 122.68 | 125.99 | 119.20 | 111.81 |
| Year Ending Dec-13 | 16 | 448.95 | 457.56 | 437.82 | 444.57 |
| Year Ending Dec-14 | 17 | 563.75 | 584.00 | 515.37 | 515.08 |
| Earnings (per share) | |||||
| Quarter Ending Sep-13 | 13 | 0.06 | 0.09 | 0.03 | 0.07 |
| Quarter Ending Dec-13 | 13 | 0.10 | 0.13 | 0.06 | 0.06 |
| Year Ending Dec-13 | 14 | -0.67 | 0.54 | -0.89 | 0.48 |
| Year Ending Dec-14 | 14 | 0.78 | 1.38 | 0.18 | 0.71 |
| LT Growth Rate (%) | 1 | 12.00 | 12.00 | 12.00 | 6.28 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Mar-13 | 108.47 | 107.15 | 1.32 | 1.22 |
| Quarter Ending Dec-12 | 103.06 | 106.49 | 3.43 | 3.33 |
| Quarter Ending Sep-12 | 98.62 | 91.00 | 7.62 | 7.73 |
| Quarter Ending Jun-12 | 104.81 | 94.64 | 10.17 | 9.70 |
| Quarter Ending Mar-12 | 148.82 | 135.80 | 13.02 | 8.75 |
| Earnings (per share) | ||||
| Quarter Ending Mar-13 | 0.04 | -0.02 | 0.06 | 147.96 |
| Quarter Ending Dec-12 | 0.03 | -0.06 | 0.09 | 329.01 |
| Quarter Ending Sep-12 | 0.02 | -0.07 | 0.09 | 422.58 |
| Quarter Ending Jun-12 | 0.12 | -0.06 | 0.18 | 150.00 |
| Quarter Ending Mar-12 | 0.42 | 0.31 | 0.11 | 25.52 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-13 | 114.38 | 114.38 | 114.56 | 114.56 | 107.94 |
| Quarter Ending Dec-13 | 122.68 | 122.68 | 122.65 | 122.65 | 111.81 |
| Year Ending Dec-13 | 448.95 | 448.95 | 450.24 | 450.24 | 444.57 |
| Year Ending Dec-14 | 563.75 | 563.75 | 564.66 | 564.11 | 515.08 |
| Earnings (per share) | |||||
| Quarter Ending Sep-13 | 0.06 | 0.06 | 0.06 | 0.06 | 0.07 |
| Quarter Ending Dec-13 | 0.10 | 0.10 | 0.09 | 0.09 | 0.06 |
| Quarter Ending Dec-13 | -0.67 | -0.67 | -0.68 | -0.68 | 0.48 |
| Quarter Ending Dec-14 | 0.78 | 0.78 | 0.75 | 0.75 | 0.71 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Sep-13 | 0 | 0 | 0 | 0 |
| Quarter Ending Dec-13 | 0 | 0 | 1 | 0 |
| Year Ending Dec-13 | 0 | 0 | 0 | 1 |
| Year Ending Dec-14 | 0 | 0 | 0 | 1 |
| Earnings | ||||
| Quarter Ending Sep-13 | 0 | 0 | 1 | 0 |
| Quarter Ending Dec-13 | 0 | 0 | 2 | 1 |
| Year Ending Dec-13 | 0 | 0 | 1 | 0 |
| Year Ending Dec-14 | 0 | 0 | 2 | 0 |
- UPDATE 1-Halozyme drug delivery technology in doubt after trial halted
- Niche drugmaker ViroPharma attracts takeover interest: sources
- CORRECTED-UPDATE 1-Niche drugmaker ViroPharma attracts takeover interest - sources
- Niche drugmaker ViroPharma attracts takeover interest: sources
- UPDATE 1-Niche drugmaker ViroPharma attracts takeover interest -sources
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
|
Provider: S&P Capital IQ Factual Report
|
$127.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Earnings vs.
Estimates